|  | Taking the Fight to Rare Cancers Beating rare cancers demands expertise in oncology and rare diseases. Our white paper shows how adaptive design, study committees, and cross-industry cooperation are fueling real progress. Premier Research. Built for Biotech℠ |
Today's Rundown Featured Story | | | Saturday, September 28, 2019 In lung cancer, Amgen’s buzzy KRAS drug hit the heights. But in its latest update, it didn't follow suit in colon cancer. Amgen was testing its drug in an early-stage, phase 1 focused on patients with previously treated KRAS G12C-mutant solid tumors. |
|
|---|
|
Top Stories Friday, September 27, 2019 Beam Therapeutics is hitting Wall Street. Nearly seven months after topping up its coffers with a $135 million series B round, the company filed Friday to raise up to $100 million in its Nasdaq IPO. Sunday, September 29, 2019 BARCELONA—Quietly, and without the fanfare of gene and cell therapies, PARP inhibitors from the likes of AstraZeneca, Merck and GlaxoSmithKline/Tesaro have been racking up big trial wins in breast and ovarian cancers. Monday, September 30, 2019 Personalized medicine, greater drug portfolio complexity, and quicker clinical development is raising the stakes. How can digital provide a boost in clinical supply chain performance? Monday, September 30, 2019 A phase 3 trial of Novartis’ QMF149 in patients with uncontrolled asthma has met its primary endpoint. Novartis showed the drug combination is better at improving lung function than an inhaled corticosteroid alone. Saturday, September 28, 2019 Astellas and Seattle Genetics’ antibody-drug conjugate is at it again. On Saturday, the duo revealed data showing enfortumab vedotin paired with Merck’s Keytruda shrank 71% of tumors and wiped out 13% of them in previously untreated patients with advanced urothelial cancer Saturday, September 28, 2019 G1 Therapeutics has linked the addition of trilaciclib to chemotherapy to improved overall survival in triple-negative breast cancer patients. People who received the CDK4/6 inhibitor lived 20.1 months, on average. Sunday, September 29, 2019 The RET inhibitor Eli Lilly picked up in its Loxo Oncology buyout continues to deliver. On the heels of an encouraging performance in lung cancer, the drug shrank tumors in more than half of patients with a rare thyroid cancer who had already tried at least two kinase inhibitors. Monday, September 30, 2019 Adaptimmune’s shares have dropped 70% this year amid disappointing data for the company’s SPEAR-T cells to treat solid tumors. Now, the company is rolling out phase 1 data for its lead product it hopes will accelerate it toward commercialization. Monday, September 30, 2019 Pfizer’s Sutent and Novartis’ Afinitor and Lutathera are all approved to tackle certain neuroendocrine tumors, but no one drug covers all types of them. Chi-Med is hoping to change that—and now it has a late-stage clinical win under its belt. |  | Congratulations to the Fierce 15 You have proven that great innovations are created with breakthrough science, insightful leaders and unwavering resolve. Thank you. And we look forward to helping you advance to your next milestone. |
Resources Sponsored by: Life Image The time has finally come when medical imaging can be effectively utilized into the RWE process. Read the whitepaper on the best practices for incorporating Real World Imaging.™ Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BioAnalytix, Inc. Download the White Paper and learn how detailed characterization can guide successful development of gene therapy products. Sponsored by: ON24 Compare digital program performance and audience engagement among your life sciences peers. Sponsored by: Decision Resources Group Clinically Integrated Networks are vehicles for powerful IDNs to extend their influence into the physician sector and play a key role for IDNs trying to pave a path to becoming a self-contained healthcare ecosystem. Sponsored by: Reprints Desk, Inc. Slashing your R&D costs is easier than you think. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Blue Matter, strategic consultants in the life sciences White paper providing an overview of precision medicine in oncology, as well as a look ahead at future developments and keys to success for pharmaceutical and diagnostics companies. Sponsored by: Patheon, by Thermo Fisher Scientific Avoid potential risks to the patient as well as costly interruptions during development. Sponsored by: Outer Edge Technology Find out how outsourcing your IT requirements enhances the bottom line while creating strategic advantage. Sponsored by: Vineti Developing a cell therapy, gene therapy, or personalized cancer vaccine? Modern data management makes a critical difference in operational and regulatory outcomes. This whitepaper will help your team leverage the latest data strategies for success. Sponsored by: AlphaSense AI-powered research tools are making it easier to source confident healthcare market intelligence with accuracy and efficiency -- download now to learn more about improving your competitive research strategy. Sponsored by: Elemental Machines Your lab is talking to you, are you listening? Sponsored by: Frenova Want to be sure your renal research protocol design is fit for the real world? Sponsored by: Recro Gainesville Vetting CDMOs but unsure what to look for in prospective partners’ multiproduct facilities? Sponsored by: Accenture Clinical trials are one of the pharma industry’s most painful and costly processes. Read how technology could transform the trial process from nine years to a matter of hours. Sponsored by: Baxter BioPharma Solutions Check out Baxter BioPharma Solutions’ whitepaper to learn considerations and options for developing a product in a prefilled syringe. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. | 
